ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

direclidine

Also written as “NBI-1117568”, “HTL0016878” and “HTL0016878.HCl Solution 10 mg”.

Its studies are mostly in Schizophrenia · Mania, led by 2 companies.

Drug pageDireclidine: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 30, 20259 company-led studies, 5 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences65 open or runningphase 3since Apr 30, 2025Sep 14, 2022Oct 2027phase 3 · NCT06963034
Nxera Pharma UKits history only30 open or runningphase 1since Aug 3, 2017Aug 3, 2017none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Neurocrine Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2022First study: phase 2 study in SchizophreniaFirst studyNCT05545111 · 210 enrolled · United States
  2. Aug 11, 2024Named direclidineINNProposed as its International Nonproprietary Name in WHO's List 131 · before, NBI-1117568, HTL0016878
  3. Apr 30, 2025Phase 3 study in SchizophreniaNCT06963034 · 284 planned · United States
  4. Jul 29, 20252 phase 3 studies in SchizophreniaNCT07114874, NCT07105098
  5. Nov 11, 2025Phase 3 study in SchizophreniaNCT07227818 · 560 planned · United States, Puerto Rico, Serbia
  6. Dec 15, 2025Phase 2 study in ManiaNCT07288320 · 150 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 3 study in SchizophreniaNCT06963034
  2. Nov 2027Primary completion: phase 3 study in SchizophreniaNCT07105098
  3. Feb 2028Primary completion: phase 2 study in ManiaNCT07288320
  4. Jul 2029Primary completion: phase 3 study in SchizophreniaNCT07227818

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 Neurocrine Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07288320Mania · United States2RecruitingFeb 2028150
NCT07227818Schizophrenia · United States, Puerto Rico, Serbia3RecruitingJul 2029560
NCT07114874Schizophrenia · United States, Bulgaria, Puerto Rico and more3RecruitingDec 2031600
NCT07105098Schizophrenia · United States, Bulgaria, Hungary and more3RecruitingNov 2027284
NCT06963034Schizophrenia · United States3RecruitingOct 2027284
NCT05545111Schizophrenia · United States2CompletedJul 10, 2024210

How it is read

Names in the registry

  • “NBI-1117568”, 6 entries
  • “HTL0016878”, 2 entries
  • “HTL0016878.HCl Solution 10 mg”, 1 entry
  • “HTL0016878.Citrate Capsule 10 mg”, 1 entry

Codes read as this program: HTL0016878.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.